Specialties

Immune-enhancing nutrition does not affect complication rate of radical cystectomy

Presented By

Prof. Jill Hamilton-Reeves, University of Kansas Medical Center, KS, USA

Trial

Phase 3, SWOG S1600

Conference

ASCO 2024

Type

Peer-reviewed article

18 July 2024 14:05

Biomarkers for treatment of renal cell carcinoma

Trial

Phase 3, CLEAR, KEYNOTE-426, IMmotion010

Conference

ASCO 2024

Type

Peer-reviewed article

18 July 2024 14:00

ctDNA changes as biomarker for pembrolizumab response in advanced urothelial carcinoma

Presented By

Prof. Thomas Powles, Barts Cancer Institute, UK

Trial

Phase 3, KEYNOTE-361

Conference

ASCO 2024

Type

Peer-reviewed article

18 July 2024 13:51

Highest efficacy of nivolumab/chemotherapy in lymph-node-only metastatic urothelial carcinoma

Presented By

Prof. Matthew Galsky, Tisch Cancer Institute, NY, USA

Trial

Phase 3, CheckMate 901

Conference

ASCO 2024

Type

Peer-reviewed article

18 July 2024 13:48

Metformin does not prevent progression of low-risk prostate cancer

Presented By

Dr Anthony Joshua, Princess Margaret Cancer Centre, Canada

Trial

Phase 3, MAST

Conference

ASCO 2024

Type

Peer-reviewed article

18 July 2024 13:46

Baseline ctDNA has both prognostic and predictive value in mCRPC

Presented By

Prof. Johann de Bono, Royal Marsden Hospital, UK

Trial

Phase 3, PSMAfore

Conference

ASCO 2024

Type

Peer-reviewed article

18 July 2024 13:44

Oxybutynin significantly decreases frequency and severity of hot flashes in men on ADT

Presented By

Dr Brad Stish, Mayo Clinic, MN, USA

Trial

Phase 2, Alliance 222001

Conference

ASCO 2024

Type

Peer-reviewed article

18 July 2024 13:41

LuPSMA and enzalutamide: a promising combination

Presented By

Prof. Louise Emmet, St Vincent’s Hospital Sydney, Australia

Trial

Phase 2, ENZA-p

Conference

ESMO 2023

Type

Peer-reviewed article

19 December 2023 12:15

No benefit of erdafitinib over pembrolizumab in urothelial cancer second-line therapy

Presented By

Prof. Arlene Siefker-Radtke, MD Anderson Cancer Centre, USA

Trial

Phase 3, THOR

Conference

ESMO 2023

Type

Peer-reviewed article

19 December 2023 11:20

Combining PARP inhibition and androgen receptor-signalling inhibition improves radiographic progression-free survival in HRR-deficient mCRPC

Presented By

Prof. Karim Fizazi, Institute Gustave Roussy, France

Trial

Phase 3, TALAPRO-2

Conference

ASCO 2023

Type

Peer-reviewed article

2 August 2023 09:24

Erdafitinib outperforms chemotherapy in FGFR-altered advanced urothelial cancer

Presented By

Dr Yohann Loriot, Gustave Roussy Cancer Institute, France

Trial

Phase 3, THOR

Conference

ASCO 2023

Type

Peer-reviewed article

2 August 2023 09:20

Probiotic CBM588 seems to improve clinical effect cabozantinib/nivolumab in mRCC

Presented By

Dr Hedyeh Ebrahimi, Tehran University of Medical Sciences, Iran

Trial

Phase 1

Conference

ASCO 2023

Type

Peer-reviewed article

2 August 2023 09:11

Exploratory analysis of IMvigor130 trial finds no OS benefit from atezolizumab in subgroups

Presented By

Dr Enrico Grande, MD Anderson Cancer Center, Spain

Trial

Phase 3, IMvigor130

Conference

ASCO 2023

Type

Peer-reviewed article

2 August 2023 09:08

Immune checkpoint inhibition improves PFS in non-BRCA-mutated ovarian cancer

Presented By

Dr Philipp Harter, Kliniken Essen-Mitte, Germany

Trial

Phase 3, DUO-O

Conference

ASCO 2023

Type

Peer-reviewed article

1 August 2023 12:44

ASCO 2023 Highlights Podcast

Presented By

Dr Rachel Giles, Medicom

Conference

ASCO 2023

26 June 2023 03:07

The road to improving doctor-patient interactions in kidney cancer

Expert

Dena Battle , KCCure - Kidney Cancer Research Alliance, USA

12 June 2023 10:37

OS benefit for advanced ovarian cancer patients treated with maintenance olaparib

Presented By

Prof. Isabelle Ray-Coquard, Centre Léon Bérard, France

Trial

Phase 3, PAOLA-1/ENGOT-ov25

Conference

ESMO 2022

Type

Peer-reviewed article

17 November 2022 00:57

Maintenance tegafur-uracil does not improve survival in locally advanced cervical cancer

Presented By

Prof. Keiichi Fujiwara, Saitama Medical University, Japan

Trial

GOTIC-002 LUFT

Conference

ESMO 2022

Type

Peer-reviewed article

17 November 2022 00:52

Adjuvant nivolumab plus ipilimumab does not improve survival in patients with localised RCC at high risk of relapse after nephrectomy

Presented By

Prof. Robert Motzer, Memorial Sloan Kettering Cancer Center, NY, USA

Trial

Phase 3, CheckMate 914

Conference

ESMO 2022

Type

Peer-reviewed article

17 November 2022 00:46

Triple therapy improves progression-free survival in patients with advanced RCC versus dual therapy

Presented By

Prof Toni Choueiri, Dana-Farber Cancer Institute, MA, USA

Trial

Phase 3, COSMIC-313

Conference

ESMO 2022

Type

Peer-reviewed article

17 November 2022 00:41

Adjuvant atezolizumab does not improve outcomes for patients with RCC and increased risk of recurrence

Presented By

Dr Axel Bex, The Royal Free London NHS Foundation Trust, UK

Trial

Phase 3, IMmotion-010

Conference

ESMO 2022

Type

Peer-reviewed article

17 November 2022 00:28

Overall survival benefit of abiraterone in mHSPC is maintained for 7 years

Presented By

Prof. Gerhardt Attard, UCL Cancer Institute London, UK

Trial

Phase 3, STAMPEDE

Conference

ESMO 2022

Type

Peer-reviewed article

17 November 2022 00:23

Limited benefit of adding long-term ADT to post-operative radiotherapy in prostate cancer

Presented By

Prof. Chris Parker, The Royal Marsden Hospital, UK

Trial

RADICALS-HD

Conference

ESMO 2022

Type

Peer-reviewed article

17 November 2022 00:17

Intensified ADT benefits biochemical progression-free survival in biochemically relapsed prostate cancer

Presented By

Dr Rahul Aggarwal, University of California San Francisco, CA, USA

Trial

Phase 3, PRESTO

Conference

ESMO 2022

Type

Peer-reviewed article

17 November 2022 00:13

Exploratory treatment options fail in ccRCC 

Presented By

Prof. Thomas Powles, University of London, UK

Trial

Phase 2, CALYPSO

Conference

ASCO 2022

Type

Peer-reviewed article

5 August 2022 14:18

Adjuvant everolimus did not benefit high-risk renal cell carcinoma 

Presented By

Dr Christopher W. Ryan, Oregon Health & Science University, OR, USA

Trial

Phase 3, EVEREST

Conference

ASCO 2022

Type

Peer-reviewed article

5 August 2022 14:14

Cabozantinib fails as first-line maintenance therapy in urothelial cancer

Presented By

Prof. Robert Jones, University of Glasgow, UK

Trial

Phase 2, ATLANTIS

Conference

ASCO 2022

Type

Peer-reviewed article

5 August 2022 14:11

177Lu-PSMA-617 is a valid treatment option for PSMA-positive mCRPC

Presented By

Prof. Michael Hofman, Peter McCallum Cancer Centre, Australia

Trial

Phase 2, TheraP

Conference

ASCO 2022

Type

Peer-reviewed article

5 August 2022 14:08

Enzalutamide performs well in metastatic hormone-sensitive prostate cancer

Presented By

Prof. Ian Davis, Monash University, Australia

Trial

Phase 3, ENZAMET

Conference

ASCO 2022

Type

Peer-reviewed article

5 August 2022 14:04

Does systematic biopsy add value to the detection rate of prostate cancer?

Presented By

Dr Enrico Checcucci, University of Turin, Italy

Conference

EAU 2022

Type

News article

22 July 2022 12:42

PSMA PET/CT cannot replace mpMRI for diagnosis of prostate cancer

Presented By

Prof. Lih-Ming Wong, University of Melbourne, Australia

Trial

Phase 3

Conference

EAU 2022

Type

News article

22 July 2022 12:41

Prostate cancer treatments reduce quality of life

Presented By

Mr André Deschamps, Europa Uomo, Belgium

Trial

EUPROMS 2.0

Conference

EAU 2022

Type

News article

22 July 2022 12:39

PROpel: Good results for abiraterone plus olaparib in mCRPC

Presented By

Prof. Noel Clarke, University of Manchester, UK

Trial

Phase 3, PROpel

Conference

EAU 2022

Type

News article

22 July 2022 12:37

Neoadjuvant hormonal therapy promising in high-risk prostate cancer

Presented By

Prof. Steven Joniau, UZ Leuven, Belgium

Trial

Phase 2, ARNEO

Conference

EAU 2022

Type

News article

22 July 2022 12:35

Darolutamide performs well across subgroups in mHSPC

Presented By

Prof. Bertrand Tombal, Université Catholique de Louvain, Belgium

Trial

Phase 3, ARASENS

Conference

EAU 2022

Type

News article

22 July 2022 12:33

Shorter hospital stay with robotic surgery versus open surgery in bladder cancer

Presented By

Prof. James Catto, University of Sheffield, UK

Trial

Phase 3, iROC

Conference

EAU 2022

Type

News article

22 July 2022 12:30

Improved risk stratification for high-risk NMIBC

Presented By

Mr Florus de Jong, Erasmus University Medical Center, the Netherlands

Conference

EAU 2022

Type

News article

22 July 2022 12:28

Adjuvant atezolizumab may benefit ctDNA-positive patients with post-op muscle-invasive urothelial carcinoma

Presented By

Prof. Jürgen Gschwend, Technical University Munich, Germany

Trial

Phase 3, IMvigor010

Conference

EAU 2022

Type

News article

22 July 2022 12:26

New prognostication in N3 penile cancer

Presented By

Dr James Churchill, St George Hospital, Australia

Conference

EAU 2022

Type

News article

22 July 2022 12:24

KEYNOTE-564: Updated results of adjuvant pembrolizumab in RCC

Presented By

Prof. Thomas Powles, Barts Cancer Institute, UK

Trial

Phase 3, KEYNOTE-564

Conference

EAU 2022

Type

News article

22 July 2022 12:22

Fewer complications with robotic surgery in renal cancer

Presented By

Prof. Marc-Oliver Grimm, Universitätsklinikum Jena, Germany

Trial

Phase 3, OpeRa

Conference

EAU 2022

Type

News article

22 July 2022 12:19

Enzalutamide with active surveillance reduces prostate-cancer progression

Journal

JAMA Oncology

22 June 2022 16:04

Novartis suspends two cancer therapies over quality concerns

5 May 2022 19:05

Support for risk-adapted androgen deprivation plus high-dose radiotherapy in prostate cancer

Journal

The Lancet Oncology

22 April 2022 15:46

Is bone health being overlooked in men on ADT for prostate cancer?

Journal

JAMA Network Open

8 April 2022 16:01

First-line treatment with olaparib significantly improves PFS in mCRPC

Presented By

Dr Fred Saad, Centre Hospitalier de l’Université de Montréal, Canada

Trial

Phase 3, PROpel

Conference

ASCO GU 2022

Type

Peer-reviewed article

8 April 2022 11:25

First-line treatment with niraparib significantly improves PFS in HRR-mutated mCRPC

Presented By

Dr Kim Chi, University of British Columbia, Canada

Trial

Phase 3, MAGNITUDE

Conference

ASCO GU 2022

Type

Peer-reviewed article

8 April 2022 11:25

Darolutamide improves OS in mHSPC

Presented By

Dr Matthew Smith, Massachusetts General Hospital Cancer Center, MA, USA

Trial

Phase 3, ARASENS

Conference

ASCO GU 2022

Type

Peer-reviewed article

8 April 2022 11:24

Continued enzalutamide plus docetaxel offers clinical benefit for mCRPC patients who progress on enzalutamide

Presented By

Dr Axel Merseburger, Universitätsklinikum Schleswig-Holstein, Germany

Trial

Phase 3, PRESIDE

Conference

ASCO GU 2022

Type

Peer-reviewed article

8 April 2022 11:24

Radiohybrid PSMA PET imaging has favourable detection rate for prostate cancer recurrence

Presented By

Dr David Schuster, Emory University School of Medicine, GA, USA

Trial

Phase 3, SPOTLIGHT

Conference

ASCO GU 2022

Type

Peer-reviewed article

8 April 2022 11:24

PSMA PET is a predictive biomarker in mCRPC progressing after docetaxel

Presented By

Prof. Michael Hofman, Peter MacCallum Cancer Centre, Australia

Trial

Phase 2, TheraP

Conference

ASCO GU 2022

Type

Peer-reviewed article

8 April 2022 11:23

Artificial intelligence improves prediction of long-term outcomes

Presented By

Dr Osama Mohamad, University of California San Francisco, CA, USA

Conference

ASCO GU 2022

Type

Peer-reviewed article

8 April 2022 11:22

Significant tumour response to neoadjuvant therapy in high-risk non-metastatic prostate cancer

Presented By

Prof. Neil Fleshner, Princess Margaret Cancer Centre, Canada

Trial

Phase 2, ACDC-RP

Conference

ASCO GU 2022

Type

Peer-reviewed article

8 April 2022 11:22

Addition of abiraterone to ADT/docetaxel does not increase bone loss

Presented By

Dr Guilhem Roubaud, Institut Bergonié, France

Trial

Phase 3, PEACE-1

Conference

ASCO GU 2022

Type

Peer-reviewed article

8 April 2022 11:21

Bavdegalutamide, a novel androgen receptor degrader, demonstrates clinical activity

Presented By

Dr Xin Gao, Massachusetts General Hospital, MA, USA

Trial

Phase 2, ARDENT

Conference

ASCO GU 2022

Type

Peer-reviewed article

8 April 2022 11:21

No benefit of olaparib in previously untreated, platinum-ineligible, metastatic urothelial carcinoma

Presented By

Dr Jonathan Rosenberg, Memorial Sloan Kettering Cancer Center, NY, USA

Trial

Phase 2, BAYOU

Conference

ASCO GU 2022

Type

Peer-reviewed article

8 April 2022 11:19

Rucaparib maintenance therapy extends PFS in platinum-responsive metastatic urothelial carcinoma

Presented By

Dr Simon Crabb, University of Southampton, UK

Trial

Phase 2, ATLANTIS

Conference

ASCO GU 2022

Type

Peer-reviewed article

8 April 2022 11:18

Positive efficacy and safety of N-803 plus BCG infusion in BCG-unresponsive NMIBC

Presented By

Dr Sam Chang, Vanderbilt University Medical Center, TN, USA

Trial

Phase 3, QUILT-3.032

Conference

ASCO GU 2022

Type

Peer-reviewed article

8 April 2022 11:18

Adding lenvatinib to pembrolizumab does not improve survival in advanced urothelial carcinoma

Presented By

Dr Yohann Loriot, Institut Gustave Roussy, France

Trial

Phase 3, LEAP-011

Conference

ASCO GU 2022

Type

Peer-reviewed article

8 April 2022 11:18

Maintenance niraparib fails to improve PFS in advanced urothelial cancer

Presented By

Dr Francesca Vignani, Ordine Mauriziano Hospital, Italy

Trial

Phase 2, Meet-URO12

Conference

ASCO GU 2022

Type

Peer-reviewed article

8 April 2022 11:17

First-line avelumab shows clinical activity in advanced urothelial carcinoma

Presented By

Dr Roberto Iacovelli, Catholic University of Rome, Italy

Trial

Phase 2, ARIES

Conference

ASCO GU 2022

Type

Peer-reviewed article

8 April 2022 11:17

Favourable pathologic response rate with neoadjuvant chemotherapy in high-risk upper tract urothelial carcinoma

Presented By

Dr Wesley Yip, Memorial Sloan Kettering Cancer Center, NY, USA

Trial

Phase 2

Conference

ASCO GU 2022

Type

Peer-reviewed article

8 April 2022 11:17

Second-line nivolumab/ipilimumab boost improves ORR in metastatic urothelial carcinoma

Presented By

Prof. Marc-Oliver Grimm, University Hospital Jena, Germany

Trial

Phase 2, TITAN-TCC

Conference

ASCO GU 2022

Type

Peer-reviewed article

8 April 2022 11:17

Sacituzumab govitecan effective in platinum-refractory metastatic urothelial cancer

Presented By

Dr Petros Grivas, University of Washington, WA, USA

Trial

Phase 2, TROPHY-U-01

Conference

ASCO GU 2022

Type

Peer-reviewed article

8 April 2022 11:16

Neoadjuvant enfortumab vedotin promising in MIBC ineligible for cisplatin

Presented By

Prof. Daniel Petrylak, Yale School of Medicine, CT, USA

Trial

Phase 1/2, EV-103

Conference

ASCO GU 2022

Type

Peer-reviewed article

8 April 2022 11:16

High-risk early RCC may benefit from neoadjuvant avelumab plus axitinib

Presented By

Dr Axel Bex, Netherlands Cancer Institute, the Netherlands

Trial

Phase 2, NeoAvAx

Conference

ASCO GU 2022

Type

Peer-reviewed article

8 April 2022 11:14

DFS benefits with adjuvant pembrolizumab in RCC persist with longer follow-up

Presented By

Dr Toni Choueiri, Dana-Farber Cancer Institute, MA, USA

Trial

Phase 3, KEYNOTE-564

Conference

ASCO GU 2022

Type

Peer-reviewed article

8 April 2022 11:14

Biomarkers predict response to immune nivolumab (± ipilimumab) in advanced RCC

Presented By

Dr Marc-Oliver Grimm, University Hospital Jena, Germany

Trial

Phase 2, TITAN-RCC

Conference

ASCO GU 2022

Type

Peer-reviewed article

8 April 2022 11:13

Combined nivolumab/axitinib treatment elicits good response in metastatic RCC

Presented By

Dr Matthew Zibelman, Fox Chase Cancer Center, PA, USA

Trial

Phase 1/2

Conference

ASCO GU 2022

Type

Peer-reviewed article

8 April 2022 11:13

Folliculin mutations not associated with sporadic chromophobe RCC

Presented By

Dr Joseph Jacob, Upstate University Hospital, NY, USA

Conference

ASCO GU 2022

Type

Peer-reviewed article

8 April 2022 11:13

Differential patterns of molecular alterations among sites of metastasis in RCC

Presented By

Dr Rana McKay, University of California San Diego, CA, USA

Conference

ASCO GU 2022

Type

Peer-reviewed article

8 April 2022 11:12

Nivolumab monotherapy represents an alternative first-line treatment option for treatment-naïve mRCC

Presented By

Dr Michael Atkins, Georgetown Lombardi Comprehensive Cancer Center, DC, USA

Trial

Phase 2, HCRN GU16-260

Conference

ASCO GU 2022

Type

Peer-reviewed article

8 April 2022 11:12

HPV-positive and HPV-negative penile squamous cell carcinoma are molecularly distinct tumours

Presented By

Dr Bassel Nazha, Emory University, GA, USA

Conference

ASCO GU 2022

Type

Peer-reviewed article

8 April 2022 11:11

Atezolizumab does not improve survival in advanced penile cancer

Presented By

Dr Hielke-Martijn de Vries, Netherlands Cancer Institute, the Netherlands

Trial

Phase 2, PERICLES

Conference

ASCO GU 2022

Type

Peer-reviewed article

8 April 2022 11:11

Biomarkers to distinguish necrosis from teratoma before pcRPLND in testicular cancer

Presented By

Dr Tim Nestler, University of Cologne, Germany

Conference

ASCO GU 2022

Type

Peer-reviewed article

8 April 2022 11:10

No survival benefit found in routine screening MRI for spinal cord compression in prostate cancer

Journal

The Lancet Oncology

7 April 2022 16:18

Immune system-generated antibodies combat ovarian tumors in a lab study

Journal

Cell

4 April 2022 23:18

Changes in genitourinary cancer management during the pandemic: findings and implications

Expert

Dr Chris Labaki, Dana-Farber Cancer Institute, MA, USA

Conference

ASCO GU 2022

4 April 2022 00:22

Large phase 3 trial tests novel combinations for metastatic RCC

Expert

Prof. Toni Choueiri, Dana-Farber Cancer Institute, Harvard Medical School, MA, USA

Trial

KEYNOTE-581/CLEAR

Conference

ASCO GU 2022

4 April 2022 00:10

Rucaparib bests chemo in relapsed ovarian cancer

Journal

The Lancet Oncology

28 March 2022 17:10

Positive phase-3 data for PARP inhibitor niraparib in ovarian cancer

Conference

Society of Gynecologic Oncology (SGO) Annual Meeting

25 March 2022 16:47

New ultrasound approach simplifies ovarian cancer detection in average-risk women

Journal

Radiology

24 March 2022 15:58

U.S. FDA approves Novartis therapy for prostate cancer

23 March 2022 23:32

Can nitrogen-based bisphosphonates protect against ovarian cancer?

Journal

Journal of the National Cancer Institute

18 March 2022 16:40

ASCO GU 2022 Highlights Podcast

Presented By

Dr Rachel Giles, Medicom

Conference

ASCO GU 2022

14 March 2022 07:21

Breast, cervical screening suboptimal in transgender individuals

Journal

American Journal of Clinical Oncology

10 March 2022 23:32

Many cancer centers not following prostate-screening recommendations

Journal

JAMA Internal Medicine

9 March 2022 15:49

Bayer’s Nubeqa drug significantly prolongs survival in prostate cancer trial

Journal

The New England Journal of Medicine

17 February 2022 23:09

Removing fallopian tubes during hysterectomy may curb ovarian cancer risk

Journal

JAMA Network Open

17 February 2022 23:06

Online tool helps ovarian-cancer patients manage symptoms

Journal

Journal of Clinical Oncology

11 February 2022 15:58

Cemiplimab boosts survival in recurrent cervical cancer

Journal

The New England Journal of Medicine

9 February 2022 23:00

Pregnancy outcomes improving after treatment for high-grade cervical neoplasia

Journal

Annals of Internal Medicine

7 February 2022 23:00

Brachytherapy boost may allow for shorter androgen deprivation therapy with EBRT

Journal

JAMA Oncology

1 February 2022 00:01

BRCA1/2 pathogenic variants linked to prostate, pancreatic and stomach cancers

Journal

Journal of Clinical Oncology

31 January 2022 15:55

AI can identify, grade prostate cancer like a pathologist

Journal

Nature Medicine

24 January 2022 23:12

Abiraterone therapy tied to longer survival in Black vs. white men with metastatic castration-resistant prostate cancer

Journal

JAMA Network Open

13 January 2022 16:16

Blacks in clinical trials respond better than whites to radiation for localized prostate cancer

Journal

JAMA Network Open

11 January 2022 16:30

Fallopian organoids promising for ovarian cancer prediction in women with BRCA mutations

Journal

Cell Reports

5 January 2022 22:16

Second-generation antiandrogens linked to higher depression risk

Journal

JAMA Network Open

31 December 2021 16:33

Drop in PSA tied to better outcomes of apalutamide therapy in prostate cancer

Journal

European Urology

30 December 2021 15:59